Patent Publication Number: US-7909836-B2

Title: Multi-actuating trigger anchor delivery system

Description:
CROSS-REFERENCES TO RELATED APPLICATIONS 
     This application is a continuation-in-part of copending U.S. patent application Ser. No. 11/671,914, filed Feb. 6, 2007, a continuation-in-part of copending U.S. patent application Ser. No. 11/492,690, filed on Jul. 24, 2006, a continuation-in-part of copending U.S. patent application Ser. No. 11/833,660, filed on Aug. 3, 2007, and a continuation-in-part of copending U.S. patent application Ser. No. 11/134,870, filed on May 20, 2005, the entire disclosures of which are expressly incorporated herein by reference. 
    
    
     FIELD OF THE INVENTION 
     The present invention relates generally to medical devices and methods, and more particularly to systems and associated methods for manipulating or retracting tissues and anatomical or other structures within the body of human or animal subjects for the purpose of treating diseases or disorders and/or for cosmetic or reconstructive or other purposes. 
     BACKGROUND OF THE INVENTION 
     There are a wide variety of situations in which it is desirable to lift, compress or otherwise reposition normal or aberrant tissues or anatomical structures (e.g., organs, ligaments, tendons, muscles, tumors, cysts, fat pads, etc.) within the body of a human or animal subject. Such procedures are often carried out for the purpose of treating or palliating the effects of diseases or disorders (e.g., hyperplasic conditions, hypertrophic conditions, neoplasias, prolapses, herniations, stenoses, constrictions, compressions, transpositions, congenital malformations, etc.) and/or for cosmetic purposes (e.g., face lifts, breast lifts, brow lifts, etc.) and/or for research and development purposes (e.g., to create animal models that mimic various pathological conditions). In many of these procedures, surgical incisions are made in the body and laborious surgical dissection is performed to access and expose the affected tissues or anatomical structures. Thereafter, in some cases, the affected tissues or anatomical structures are removed or excised. In other cases, various natural or man made materials are used to lift, sling, reposition or compress the affected tissues. 
     Benign Prostatic Hyperplasia (BPH) 
     One example of a condition where it is desirable to lift, compress or otherwise remove a pathologically enlarged tissue is Benign Prostatic Hyperplasia (BPH). BPH is one of the most common medical conditions that affect men, especially elderly men. It has been reported that, in the United States, more than half of all men have histopathologic evidence of BPH by age 60 and, by age 85, approximately 9 out of 10 men suffer from the condition. Moreover, the incidence and prevalence of BPH are expected to increase as the average age of the population in developed countries increases. 
     The prostate gland enlarges throughout a man&#39;s life. In some men, the prostatic capsule around the prostate gland may prevent the prostate gland from enlarging further. This causes the inner region of the prostate gland to squeeze the urethra. This pressure on the urethra increases resistance to urine flow through the region of the urethra enclosed by the prostate. Thus the urinary bladder has to exert more pressure to force urine through the increased resistance of the urethra. Chronic over-exertion causes the muscular walls of the urinary bladder to remodel and become stiffer. This combination of increased urethral resistance to urine flow and stiffness and hypertrophy of urinary bladder walls leads to a variety of lower urinary tract symptoms (LUTS) that may severely reduce the patient&#39;s quality of life. These symptoms include weak or intermittent urine flow while urinating, straining when urinating, hesitation before urine flow starts, feeling that the bladder has not emptied completely even after urination, dribbling at the end of urination or leakage afterward, increased frequency of urination particularly at night, urgent need to urinate etc. 
     In addition to patients with BPH, LUTS may also be present in patients with prostate cancer, prostate infections, and chronic use of certain medications (e.g. ephedrine, pseudoephedrine, phenylpropanolamine, antihistamines such as diphenhydramine, chlorpheniramine etc.) that cause urinary retention especially in men with prostate enlargement. 
     Although BPH is rarely life threatening, it can lead to numerous clinical conditions including urinary retention, renal insufficiency, recurrent urinary tract infection, incontinence, hematuria, and bladder stones. 
     In developed countries, a large percentage of the patient population undergoes treatment for BPH symptoms. It has been estimated that by the age of 80 years, approximately 25% of the male population of the United States will have undergone some form of BPH treatment. At present, the available treatment options for BPH include watchful waiting, medications (phytotherapy and prescription medications), surgery and minimally invasive procedures. 
     For patients who choose the watchful waiting option, no immediate treatment is provided to the patient, but the patient undergoes regular exams to monitor progression of the disease. This is usually done on patients that have minimal symptoms that are not especially bothersome. 
     Medications for treating BPH symptoms include phytotherapy and prescription medications. In phytotherapy, plant products such as Saw Palmetto, African Pygeum, Serenoa Repens (sago palm) and South African star grass are administered to the patient. Prescription medications are prescribed as first line therapy in patients with symptoms that are interfering with their daily activities. Two main classes of prescription medications are alpha-1a-adrenergic receptors blockers and 5-alpha-reductase inhibitors. Alpha-1a-adrenergic receptors blockers block that activity of alpha-1a-adrenergic receptors that are responsible for causing constriction of smooth muscle cells in the prostate. Thus, blocking the activity of alpha-1a-adrenergic receptors causes prostatic smooth muscle relaxation. This in turn reduces urethral resistance thereby reducing the severity of the symptoms. 5-alpha-reductase inhibitors block the conversion of testosterone to dihydrotestosterone. Dihydrotestosterone causes growth of epithelial cells in the prostate gland. Thus 5-alpha-reductase inhibitors cause regression of epithelial cells in the prostate gland and hence reduce the volume of the prostate gland which in turn reduces the severity of the symptoms. 
     Surgical procedures for treating BPH symptoms include Transurethal Resection of Prostate (TURP), Transurethral Electrovaporization of Prostate (TVP), Transurethral Incision of the Prostate (TUIP), Laser Prostatectomy and Open Prostatectomy. 
     Transurethal Resection of Prostate (TURP) is the most commonly practiced surgical procedure implemented for the treatment of BPH. In this procedure, prostatic urethral obstruction is reduced by removing most of the prostatic urethra and a sizeable volume of the surrounding prostate gland. This is carried out under general or spinal anesthesia. In this procedure, a urologist visualizes the urethra by inserting a resectoscope, that houses an optical lens in communication with a video camera, into the urethra such that the distal region of the resectoscope is in the region of the urethra surrounded by the prostate gland. The distal region of the resectoscope consists of an electric cutting loop that can cut prostatic tissue when an electric current is applied to the device. An electric return pad is placed on the patient to close the cutting circuit. The electric cutting loop is used to scrape away tissue from the inside of the prostate gland. The tissue that is scraped away is flushed out of the urinary system using an irrigation fluid. Using a coagulation energy setting, the loop is also used to cauterize transected vessels during the operation. 
     Another example of a surgical procedure for treating BPH symptoms is Transurethral Electrovaporization of the Prostate (TVP). In this procedure, a part of prostatic tissue squeezing the urethra is desiccated or vaporized. This is carried out under general or spinal anesthesia. In this procedure, a resectoscope is inserted transurethrally such that the distal region of the resectoscope is in the region of the urethra surrounded by the prostate gland. The distal region of the resectoscope consists of a rollerball or a grooved roller electrode. A controlled amount of electric current is passed through the electrode. The surrounding tissue is rapidly heated up and vaporized to create a vaporized space. Thus the region of urethra that is blocked by the surrounding prostate gland is opened up. 
     Another example of a surgical procedure for treating BPH symptoms is Transurethral Incision of the Prostate (TUIP). In this procedure, the resistance to urine flow is reduced by making one or more incisions in the prostate gland in the region where the urethra meets the urinary bladder. This procedure is performed under general or spinal anesthesia. In this procedure, one or more incisions are made in the muscle of the bladder neck, which is the region where the urethra meets the urinary bladder. The incisions are in most cases are deep enough to cut the surrounding prostate gland tissue including the prostatic capsule. This releases any compression on the bladder neck and causes the bladder neck to spring apart. The incisions can be made using a resectoscope, laser beam etc. 
     Another example of a surgical procedure for treating BPH symptoms is Laser Prostatectomy. Two common techniques used for Laser Prostatectomy are Visual Laser Ablation of the Prostate (VLAP) and the Holmium Laser Resection/Enucleation of the Prostate (HoLEP). In VLAP, a neodymium:yttrium-aluminum-garnet (Nd:YAG) laser is used to ablate tissue by causing coagulation necrosis. The procedure is performed under visual guidance. In HoLEP, a holmium:Yttrium-aluminum-garnet laser is used for direct contact ablation of tissue. Both these techniques are used to remove tissue obstructing the urethral passage to reduce the severity of BPH symptoms. 
     Another example of a surgical procedure for treating BPH symptoms is Photoselective Vaporization of the Prostate (PVP). In this procedure, laser energy is used to vaporize prostatic tissue to relieve obstruction to urine flow in the urethra. The type of laser used is the Potassium-Titanyl-Phosphate (KTP) laser. The wavelength of this laser is highly absorbed by oxyhemoglobin. This laser vaporizes cellular water and hence is used to remove tissue that is obstructing the urethra. 
     Another example of a surgical procedure for treating BPH symptoms is Open Prostatectomy. In this procedure, the prostate gland is surgically removed by an open surgery. This is done under general anesthesia. The prostate gland is removed through an incision in the lower abdomen or the perineum. The procedure is used mostly in patients that have a large (greater than approximately 100 grams) prostate gland. 
     Minimally invasive procedures for treating BPH symptoms include Transurethral Microwave Thermotherapy (TUMT), Transurethral Needle Ablation (TUNA), Interstitial Laser Coagulation (ILC), and Prostatic Stents. 
     In Transurethral Microwave Thermotherapy (TUMT), microwave energy is used to generate heat that destroys hyperplastic prostate tissue. This procedure is performed under local anesthesia. In this procedure, a microwave antenna is inserted in the urethra. A rectal thermosensing unit is inserted into the rectum to measure rectal temperature. Rectal temperature measurements are used to prevent overheating of the anatomical region. The microwave antenna is then used to deliver microwaves to lateral lobes of the prostate gland. The microwaves are absorbed as they pass through prostate tissue. This generates heat which in turn destroys the prostate tissue. The destruction of prostate tissue reduces the degree of squeezing of the urethra by the prostate gland thus reducing the severity of BPH symptoms. 
     Another example of a minimally invasive procedure for treating BPH symptoms is Transurethral Needle Ablation (TUNA). In this procedure, heat induced coagulation necrosis of prostate tissue regions causes the prostate gland to shrink. It is performed using local anesthetic and intravenous or oral sedation. In this procedure, a delivery catheter is inserted into the urethra. The delivery catheter comprises two radiofrequency needles that emerge at an angle of 90 degrees from the delivery catheter. The two radiofrequency needles are aligned at an angle of 40 degrees to each other so that they penetrate the lateral lobes of the prostate. A radiofrequency current is delivered through the radiofrequency needles to heat the tissue of the lateral lobes to 70-100 degree Celsius at a radiofrequency power of approximately 456 KHz for approximately 4 minutes per lesion. This creates coagulation defects in the lateral lobes. The coagulation defects cause shrinkage of prostatic tissue which in turn reduces the degree of squeezing of the urethra by the prostate gland thus reducing the severity of BPH symptoms. 
     Another example of a minimally invasive procedure for treating BPH symptoms is Interstitial Laser Coagulation (ILC). In this procedure, laser induced necrosis of prostate tissue regions causes the prostate gland to shrink. It is performed using regional anesthesia, spinal or epidural anesthesia or local anesthesia (periprostatic block). In this procedure, a cystoscope sheath is inserted into the urethra and the region of the urethra surrounded by the prostate gland is inspected. A laser fiber is inserted into the urethra. The laser fiber has a sharp distal tip to facilitate the penetration of the laser scope into prostatic tissue. The distal tip of the laser fiber has a distal-diffusing region that distributes laser energy 360° along the terminal 3 mm of the laser fiber. The distal tip is inserted into the middle lobe of the prostate gland and laser energy is delivered through the distal tip for a desired time. This heats the middle lobe and causes laser induced necrosis of the tissue around the distal tip. Thereafter, the distal tip is withdrawn from the middle lobe. The same procedure of inserting the distal tip into a lobe and delivering laser energy is repeated with the lateral lobes. This causes tissue necrosis in several regions of the prostate gland which in turn causes the prostate gland to shrink. Shrinkage of the prostate gland reduces the degree of squeezing of the urethra by the prostate thus reducing the severity of BPH symptoms. 
     Another example of a minimally invasive procedure for treating BPH symptoms is implanting Prostatic Stents. In this procedure, the region of urethra surrounded by the prostate is mechanically supported to reduce the constriction caused by an enlarged prostate. Prostatic stents are flexible devices that are expanded after their insertion in the urethra. They mechanically support the urethra by pushing the obstructing prostatic tissue away from the urethra. This reduces the constriction of the urethra and improves urine flow past the prostate gland thereby reducing the severity of BPH symptoms. 
     Although existing treatments provide some relief to the patient from symptoms of BPH, they have disadvantages. Alpha-1a-adrenergic receptors blockers have side effects such as dizziness, postural hypotension, lightheadedness, asthenia and nasal stuffiness. Retrograde ejaculation can also occur. 5-alpha-reductase inhibitors have minimal side effects, but only a modest effect on BPH symptoms and the flow rate of urine. In addition, anti-androgens, such as 5-alpha-reductase, require months of therapy before LUTS improvements are observed. Surgical treatments of BPH carry a risk of complications including erectile dysfunction; retrograde ejaculation; urinary incontinence; complications related to anesthesia; damage to the penis or urethra, need for a repeat surgery etc. Even TURP, which is the gold standard in treatment of BPH, carries a high risk of complications. Adverse events associated with this procedure are reported to include retrograde ejaculation (65% of patients), post-operative irritation (15%), erectile dysfunction (10%), need for transfusion (8%), bladder neck constriction (7%), infection (6%), significant hematuria (6%), acute urinary retention (5%), need for secondary procedure (5%), and incontinence (3%) Typical recovery from TURP involves several days of inpatient hospital treatment with an indwelling urethral catheter, followed by several weeks in which obstructive symptoms are relieved but there is pain or discomfort during micturition. 
     The reduction in the symptom score after minimally invasive procedures is not as large as the reduction in symptom score after TURP. Up to 25% of patients who receive these minimally invasive procedures ultimately undergo a TURP within 2 years. The improvement in the symptom score generally does not occur immediately after the procedure. For example, it takes an average of one month for a patient to notice improvement in symptoms after TUMT and 1.5 months to notice improvement after ILC. In fact, symptoms are typically worse for these therapies that heat or cook tissue, because of the swelling and necrosis that occurs in the initial weeks following the procedures. Prostatic stents often offer more immediate relief from obstruction but are now rarely used because of high adverse effect rates. Stents have the risk of migration from the original implant site (up to 12.5% of patients), encrustation (up to 27.5%), incontinence (up to 3%), and recurrent pain and discomfort. In published studies, these adverse effects necessitated 8% to 47% of stents to be explanted. Overgrowth of tissue through the stent and complex stent geometries have made their removal quite difficult and invasive. 
     Thus the most effective current methods of treating BPH carry a high risk of adverse effects. These methods and devices either require general or spinal anesthesia or have potential adverse effects that dictate that the procedures be performed in a surgical operating room, followed by a hospital stay for the patient. The methods of treating BPH that carry a lower risk of adverse effects are also associated with a lower reduction in the symptom score. While several of these procedures can be conducted with local analgesia in an office setting, the patient does not experience immediate relief and in fact often experiences worse symptoms for weeks after the procedure until the body begins to heal. Additionally all device approaches require a urethral catheter placed in the bladder, in some cases for weeks. In some cases catheterization is indicated because the therapy actually causes obstruction during a period of time post operatively, and in other cases it is indicated because of post-operative bleeding and potentially occlusive clot formation. While drug therapies are easy to administer, the results are suboptimal, take significant time to take effect, and often entail undesired side effects. 
     Urinary Incontinence (UI) 
     Many women experience loss of bladder control following childbirth or in old age. This condition is broadly referred to as urinary incontinence (UI). The severity of UI varies and, in severe cases, the disorder can be totally debilitating, keeping the patient largely homebound. It is usually associated with a cystocele, which results from sagging of the neck of the urinary bladder into or even outside the vagina 
     The treatments for UI include behavioral therapy, muscle strengthening exercises (e.g., Kegel exercises), drug therapy, electrical stimulation of the pelvic nerves, use of intravaginal devices and surgery. 
     In severe cases of UI, surgery is generally the best treatment option. In general, the surgical procedures used to treat UI attempt to lift and support the bladder so that the bladder and urethra are returned to their normal positions within the pelvic cavity. The two most common ways of performing these surgeries is through incisions formed in the abdominal wall or though the wall of the vagina. 
     A number of different surgical procedures have been used to treat UI. The names for these procedures include the Birch Procedure, Marshall-Marchetti Operation, MMK, Pubo-Vaginal Sling, Trans-Vaginal Tape Procedure, Urethral Suspension, Vesicourethral Suspension. These procedures generally fall into two categories, namely a) retropubic suspension procedures and b) sling procedures. 
     In retropubic suspension procedures, an incision is typically made in the abdominal wall a few inches below the navel and a network of connectors are placed to support the bladder neck. The connectors are anchored to the pubic bone and to other structures within the pelvis, essentially forming a cradle which supports the urinary bladder. 
     In sling procedures, an incision is typically made in the wall of the vagina and a sling is crafted of either natural tissue or synthetic (man-made) material to support the bladder neck. Both ends of the sling may be attached to the pubic bone or tied in front of the abdomen just above the pubic bone. In some sling procedures a synthetic tape is used to form the sling and the ends of the synthetic tape are not tied but rather pulled up above the pubic bone. 
     The surgeries used to treat UI are generally associated with significant discomfort as the incisions heal and may require a Foley or supra-pubic urinary catheter to remain in place for at least several days following the surgery. Thus, there exists a need in the art for the development of minimally invasive (e.g., non-incisional) procedures for the treatment of UI with less postoperative discomfort and less requirement for post-surgical urinary catheterization. 
     Cosmetic or Reconstructive Tissue Lifting and Repositioning 
     Many cosmetic or reconstructive surgical procedures involve lifting, compressing or repositioning of natural tissue, natural tissue or artificial grafts or aberrant tissue. For example, surgical procedures such as face lifts, brow lifts, neck lifts, tummy tucks, etc. have become commonplace. In many cases, these procedures are performed by creating incisions through the skin, dissecting to a plane beneath muscles and fascia, freeing the muscles, fascia and overlying skin from underlying structures (e.g., bone or other muscles), lifting or repositioning the freed muscles, fascia and overlying skin and then attaching the repositioned tissues to underlying or nearby structures (e.g., bone, periostium, other muscles) to hold the repositioned tissues in their new (e.g., lifted) position. In some cases excess skin may also be removed during the procedure. 
     There have been attempts to develop minimally invasive devices and methods for cosmetic lifting and repositioning of tissues. For example, connector suspension lifts have been developed where one end of a standard or modified connector thread is attached to muscle and the other end is anchored to bone, periostium or another structure to lift and reposition the tissues as desired. Some of these connector suspension techniques have been performed through cannulas or needles inserted though relatively small incisions of puncture wounds. 
     There remains a need for the development of new devices and methods that may be used for various procedures where it is desired to lift, compress, support or reposition tissues or organs within the body with less intraoperative trauma, less post-operative discomfort and/or shorter recovery times. Further, there is a need for an apparatus and related method which is easy and convenient to employ in an interventional procedure. In particular, there is a need for a substantially automated apparatus which can accomplish accessing an interventional site as well as the assembly and delivery of an interventional device at the site. 
     The present invention addresses these and other needs. 
     SUMMARY OF THE INVENTION 
     Briefly and in general terms, the present invention is directed towards an apparatus and method for deploying an anchor assembly within a patient&#39;s body. The apparatus of the present invention includes various subassemblies which are mobilized via a multi-actuating trigger. The operation of the subassemblies is coordinated and synchronized to minimize operator steps and to ensure accurate and precise implantation of a single or multiple anchor assemblies. 
     In one embodiment, the multi-actuating trigger anchor delivery system of the present invention includes a handle assembly operatively connected to a core assembly. The handle assembly can be permanently connected to the core assembly or the core assembly can be attachable to the handle assembly such that the handle can be used with multiple core assemblies over time. The core assembly houses a plurality of components for constructing anchor assemblies. The handle assembly further includes a rocker arm assembly, a spool or rotary assembly and a trigger assembly which cooperate to accomplish the various functions of the delivery system. In particular, in one aspect the spool assembly includes one or more spring assemblies loaded with sufficient energy to advance and deploy components for multiple anchor assemblies. The spool assembly is particularly advantageous in that it allows several anchor assemblies of at least 6 cm of length each to be stored in a relatively small device that fits in a user&#39;s hand. It is further advantageous in that it allows the physician to insert the device only once into the patient to deliver multiple anchor assemblies at different locations before having to withdraw the device. In another aspect the rocker arm assembly includes one or more spring assemblies loaded with sufficient energy to advance and retract the core assembly a plurality of times. The delivery system further includes a reset assembly that may recharge one or more springs within the handle and core assemblies. It can be appreciated that rocker arm and spool housing actuation can be accomplished by manual advancement, elastomers, compressed gas, or motor. 
     In one particular aspect, the present invention is directed towards a delivery device which accomplishes the delivery of a first or distal anchor assembly component at a first location within a patient&#39;s body and the delivery of a second or proximal anchor assembly component at a second location within the patient. The device also accomplishes imparting a tension during delivery and a tension between implanted anchor components as well as cutting the anchor assembly to a desired length and assembling the proximal anchor in situ. The procedure can be viewed employing a scope incorporated into the device. Also, the delivery device can be sized and shaped to be compatible with a sheath in the range of 18 to 24 F, preferably a 19 F sheath. 
     Additionally, in a contemplated embodiment of a multi-actuating trigger anchor delivery system, a first trigger pull results in a needle assembly being advanced within a patient to an interventional site. A second trigger pull accomplishes the deployment of a first anchor component of an anchor assembly at the interventional site and a third trigger pull facilitates withdrawing the needle assembly. A fourth trigger depression facilitates the assembly and release of a second component of an anchor assembly at the interventional site. A reset assembly is further provided to reset aspects of the delivery system. 
     The present invention also contemplates a reversible procedure as well as an anchor assembly with sufficient visibility when viewed ultrasonically, by xray, MRI or other imaging modalities. In one aspect, the implant procedure is reversible by severing a connector of an anchor assembly and removing an anchor of the anchor assembly such as by so removing a proximally placed anchor previously implanted in an urethra. Moreover, the anchor assemblies can be formed of structures facilitating ultrasound viewing or other imaging modalities. 
     The anchor assembly can be configured to accomplish retracting, lifting, compressing, supporting or repositioning tissue within the body of a human or animal subject. Moreover, the apparatus configured to deploy the anchor assembly as well as the anchor assembly itself are configured to complement and cooperate with body anatomy. Further, the anchor assembly may be coated or imbedded with therapeutic or diagnostic substances, in particular Botulinum toxin, or such substances can be introduced into or near an interventional site by the anchor deployment device or other structure. 
     In another aspect, structure of the anchor assembly is designed to invaginate within or complement tissue anatomy to thereby facilitate healing and minimize infection risk or risk of calculus formation. Moreover, the anchor delivery device includes structure to form desired angles between an extended position of the needle assembly relative to the device. Additionally, it is contemplated that a distal end portion of the anchor delivery device be configured to facilitate the testing of the effectiveness of positioning of an anchor assembly. In this regard, the distal end portion is configured in a manner to allow the device operator to mimic the effect a second anchor member will have prior to anchor delivery. 
     In one embodiment, the anchor delivery device includes a handle assembly with a trigger attached thereto. The trigger is associated with a body of the handle assembly and is operatively attached to the needle assembly and structure that advances the first anchor member. The trigger is also operatively associated with structure that accomplishes assembling first and second parts of the second anchor member to each other and to the connector member or by forming a single-piece second anchor member around the connector member. Additionally, the handle assembly is equipped with structure that is configured in one contemplated embodiment, to effect the cutting of the anchor assembly to a desired length and deployment of the structure at an interventional site. 
     In a specific embodiment, the anchor delivery device includes a generally elongate tubular housing assembly member extending distally from a handle assembly including a trigger. The proximal end of the handle assembly is equipped with mounting structure configured to receive a telescope or other endoscopic viewing instrument. A bore sized to receive the telescope extends distally through a body of the handle assembly and continues through an outer tubular cover member forming the generally elongate member. Housed within the tubular housing assembly are a telescope tube having an interior defining a distal section of the bore sized to receive the telescope, an upper tubular member assembly sized to receive a plurality of first components of the second anchor member and a needle housing configured to receive the needle assembly. Moreover, the generally elongate tubular housing includes a terminal end portion defined by a nose assembly which retains a plurality of second components of the second anchor members. 
     Additionally, in a preferred embodiment the first anchor member includes a tubular portion, a mid-section and a tail portion. The tail portion of the member further includes a connector section which acts as a spring. A terminal end portion of the tail is further contemplated to have a surface area larger than the connector section to provide a platform for engaging tissue. 
     Further, in the preferred embodiment, one component of the second anchor member is embodied in a pin having a first distal end equipped with a pair of spaced arms and a second proximal end including grooves facilitating pushability. 
     Moreover, various alternative methods of use are also contemplated. That is, in some applications of the invention, the invention may be used to facilitate volitional or non-volitional flow of a body fluid through a body lumen, modify the size or shape of a body lumen or cavity, treat prostate enlargement, treat urinary incontinence, support or maintain positioning of a tissue, organ or graft, perform a cosmetic lifting or repositioning procedure, form anastomotic connections, and/or treat various other disorders where a natural or pathologic tissue or organ is pressing on or interfering with an adjacent anatomical structure. Also, the invention has a myriad of other potential surgical, therapeutic, cosmetic or reconstructive applications, such as where a tissue, organ, graft or other material requires retracting, lifting, repositioning, compression or support. 
     Other features and advantages of the present invention will become apparent from the following detailed description, taken in conjunction with the accompanying drawings, which illustrate, by way of example, the principles of the invention. 
    
    
     
       BRIEF DESCRIPTION OF THE DRAWINGS 
         FIG. 1A  is an elevation view, depicting a multi-actuating trigger anchor delivery system of the present invention; 
         FIG. 1B  is an elevation view, depicting the system of  FIG. 1A  with the handle case removed; 
         FIG. 1C  is a rotated elevation view, depicting the system of  FIG. 1B  without the handle case; 
         FIG. 1D  is a detail view, depicting a distal end portion of the device of  FIG. 1C ; 
         FIG. 2A  is a perspective view, depicting a core assembly of the multi-actuating trigger anchor delivery system of  FIG. 1B ; 
         FIG. 2B  is a perspective view, depicting a shaft assembly of the core assembly of  FIG. 2A ; 
         FIG. 2C  is a perspective view, depicting another approach to forming sections of a shaft assembly; 
         FIG. 2D  is a perspective view, depicting an alternate approach to structure of a distal end portion of the system; 
         FIG. 2E  is a perspective view, depicting a first step in forming an alternative approach to a shaft assembly; 
         FIG. 2F  is a perspective view, depicting a second step in forming an alternative approach to a shaft assembly; 
         FIG. 2G  is a perspective view, depicting a third step in forming an alternative approach to a shaft assembly; 
         FIG. 2H  is a perspective view, depicting a fourth step in forming an alternative approach to a shaft assembly; 
         FIG. 2I  is a perspective view, depicting a fifth step in forming an alternative approach to a shaft assembly; 
         FIG. 3A  is an elevation view, depicting a rocker arm assembly of the multi-actuating trigger anchor delivery system of  FIG. 1B ; 
         FIG. 3B  is an elevation view, depicting the rocker arm assembly of  FIG. 3A  with a crank spring assembly removed; 
         FIG. 3C  is an elevation view, depicting the rocker arm assembly of  FIG. 3B  with a large crank gear removed; 
         FIG. 3D  is an elevation view, depicting the rocker arm assembly of  FIG. 3C  with a rocker arm ratchet removed; 
         FIG. 3E  is a rotated elevation view, depicting the rocker arm assembly of  FIG. 3D ; 
         FIG. 3F  is an isometric view, depicting the juxtaposition of the crank bearing assembly and the cam bearing assembly; 
         FIG. 4A  is a rotated perspective view, depicting the spool assembly of the multi-actuating trigger anchor delivery system of  FIG. 1B ; 
         FIG. 4B  is an exploded view, depicting the spool assembly of  FIG. 4A ; 
         FIG. 5A  is an enlarged elevation view, depicting a trigger assembly of the multi-actuating trigger anchor delivery system of  FIG. 1B ; 
         FIG. 5B  is an elevation view, depicting the trigger assembly of  FIG. 5A  with a mounting block removed; 
         FIG. 5C  is an elevation view, depicting the trigger assembly of  FIG. 5B  with a bell crank assembly removed; 
         FIG. 5D  is a rotated perspective view, depicting the trigger assembly of  FIG. 5C  with a mounting block cap removed; 
         FIG. 5E  is an enlarged view, depicting the double pawl in a default position; 
         FIG. 5F  is an enlarged view, depicting the double pawl after trigger depression; 
         FIG. 5G  is an enlarged view, depicting the bell crank frame including a bell crank follower; 
         FIG. 6A  is an enlarged perspective view, depicting a reset assembly of the multi-actuating trigger anchor delivery system of  FIG. 1C ; 
         FIG. 6B  is a perspective view, depicting the assembly of  FIG. 6A  with a reset knob and reset one way wheel removed; 
         FIG. 7A  is a perspective view, depicting one preferred embodiment of a first anchor member of an anchor assembly of the present matter; 
         FIG. 7B  is a side view, depicting the first anchor member of  FIG. 7A  attached to a connecting member; 
         FIG. 7C  is a perspective view, depicting components of one of the preferred embodiments of the second anchor member in a configuration prior to assembly; and 
         FIG. 7D  is a perspective view, depicting an assembled second anchor member of the present invention attached to a connecting member. 
         FIG. 8  is a cross-sectional view, depicting a first step of treating a prostate gland using the present invention; 
         FIG. 9A  is a left side view, depicting the multi-actuating trigger anchor delivery system of  FIG. 1A  with the left handle half and reset assembly removed; 
         FIG. 9B  is a left side view, depicting the assembly of  FIG. 9A  with the trigger depressed; 
         FIG. 9C  is a left side view, depicting the assembly of  FIG. 9A  with the trigger partially returned and the rocker arm assembly removed; 
         FIG. 9D  is a partial cross-sectional view, depicting the distal end portion of the anchor deployment device and the lateral advancement of a needle assembly; 
         FIG. 9E  is a cross-sectional view, depicting a second step of treating a prostate gland using the present invention; 
         FIG. 10A  is a left side view, depicting the assembly of  FIG. 9C  with the trigger being activated for a second time; 
         FIG. 10B  is a left side view, depicting the assembly of  FIG. 10A  with the trigger further depressed; 
         FIG. 10C  is a left side view, depicting the assembly of  FIG. 10B  with the trigger completely depressed; 
         FIG. 10D  is a perspective view, depicting a distal end portion of the anchor deployment device of  FIG. 9D  after deployment of the first anchor; 
         FIG. 10E  is a cross-sectional view of the extendable tip, depicting the assembly of  FIG. 10D ; 
         FIG. 10F  is a cross-sectional view, depicting a further step of a method of treating a prostate gland using the present invention; 
         FIG. 11A  is a left side view, depicting the assembly of  FIG. 9A  in a ready position for a third actuation; 
         FIG. 11B  is a left side view, depicting the assembly of  FIG. 1A  with the trigger partially depressed; 
         FIG. 11C  is a left side view, depicting the assembly of  FIG. 11B  with the trigger completely depressed; 
         FIG. 11D  is a perspective view, depicting the assembly of  FIG. 9D  after the complete retraction of the needle assembly; 
         FIG. 11E  is a cross-sectional view, depicting yet another step of a method of treating a prostate gland using the present invention; 
         FIG. 12A  is a left side view, depicting the assembly of  FIG. 9A  in a ready position for a fourth actuation; 
         FIG. 12B  is a left side view, depicting an intermediate stage of the depression of the trigger of the assembly of  FIG. 12A ; 
         FIG. 12C  is a left side view, depicting the complete depression of the trigger of the assembly of  FIG. 12B  with partial rotation of the cam; 
         FIG. 12D  is a partial cross-sectional view, depicting the assembly of  FIG. 9D  with the cover removed; 
         FIG. 12E  is a partial cross-sectional view, depicting the deployment device of  FIG. 12D  with a second component of the second anchor member being advanced toward a first component of the second anchor member; 
         FIG. 12F  is a left side view, depicting the assembly of  FIG. 12C  with full rotation of the cam and the outer tube assembly pulled proximally; 
         FIG. 12G  is a perspective view, depicting the assembly of  FIG. 9D  of the delivery device with the second component completely advanced into locking engagement with the first component and the connector member cut; 
         FIG. 12H  is a cross-sectional view, depicting yet a further step involved in treating a prostate gland using the present invention; 
         FIG. 13  is a left side view, depicting the multi-actuator trigger anchor delivery assembly of the present invention with the reset mechanism configured to recharge the system; 
         FIG. 14A  is a cross-sectional view, depicting the implantation of anchor assemblies at an interventional site; and 
         FIG. 14B  is an enlarged view, depicting one anchor component of the assemblies shown in  FIG. 14A . 
     
    
    
     DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS 
     Turning now to the figures, which are provided by way of example and not limitation, the present invention is embodied in a device configured to deliver anchor assemblies within a patient&#39;s body. As stated, the present invention can be employed for various medical purposes including but not limited to retracting, lifting, compressing, supporting or repositioning tissues, organs, anatomical structures, grafts or other material found within a patient&#39;s body. Such tissue manipulation is intended to facilitate the treatment of diseases or disorders. Moreover, the disclosed invention has applications in cosmetic or reconstruction purposes or in areas relating the development or research of medical treatments. 
     In one particular aspect, the anchor assembly of the present invention is contemplated to be formed of a structure which is visible by ultrasound. Accordingly, the anchor assembly can be viewed during ultrasonic body scans such as during normal trans-rectal ultrasound when a medical professional is conducting diagnoses or treatment associated with conditions like prostate cancer. 
     In such applications, one portion of an anchor assembly is positioned and implanted against a first section of anatomy. A second portion of the anchor assembly is then positioned and implanted adjacent a second section of anatomy for the purpose of retracting, lifting, compressing, supporting or repositioning the second section of anatomy with respect to the first section of anatomy as well as for the purpose of retracting, lifting, compressing, supporting or repositioning the first section of anatomy with respect to the second section of anatomy. It is also to be recognized that both a first and second portion of the anchor assembly can be configured to accomplish the desired retracting, lifting, compressing, supporting or repositioning of anatomy due to tension supplied thereto via a connector assembly affixed to the first and second portions of the anchor assembly. 
     Referring now to  FIGS. 1A-D , there is shown one embodiment of a multi-actuating trigger anchor delivery system  100  of the present invention. This device is configured to include structure that is capable of both gaining access to an interventional site as well as assembling and implanting one or more anchor assemblies within a patient&#39;s body. In one aspect, the device  100  is configured to assemble and implant four anchor assemblies. The device is further contemplated to be compatible for use with a 19 F sheath. The device additionally includes structure configured to receive a conventional remote viewing device (e.g., an endoscope) so that the steps being performed at the interventional site can be observed. 
     The multi-actuating trigger anchor delivery device  100  includes a handle assembly  102  connected to an elongate tissue access assembly  104 . The elongate tissue access assembly  104  houses components employed to construct a plurality of anchor assemblies. 
     The anchor delivery system  100  further includes a number of subassemblies. A handle case assembly  106  including mating handle halves which encase the handle assembly  102 . The handle assembly  102  is sized and shaped to fit comfortably within an operator&#39;s hand and can be formed from conventional materials. Windows  107  can be formed in the handle case assembly  106  to provide access to internal mechanism of the device so that a manual override is available to the operator in the event the interventional procedure needs to be abandoned. A core assembly  110  extends through the handle assembly  102 , and includes the components defining the elongate tissue access assembly  104 . 
     The handle assembly  102  further includes a trigger system assembly  114 , a spool assembly  116  and a rocker arm assembly  118 . These assemblies cooperate to accomplish gaining access to an interventional site as well as the assembly and implantation of an anchor assembly at the interventional site. 
     Moreover, a terminal end portion  119  of the anchor delivery system includes a distal tip assembly  128  shaped to provide an atraumatic surface as well as one which facilitates desired positioning of components of an anchor assembly (See  FIG. 1D ). That is, by including structure that can mimic the ultimate position of a proximally oriented component of an anchor assembly, an operator can test the effect of the anchor assembly prior to implantation. Once the operator confirms that the subject anchor component will be positioned as desired, the implantation of the anchor is then undertaken and accomplished. 
     Turning now to  FIGS. 2A-2B , there is shown a core assembly  110 . As stated, the core assembly  110  retains the components necessary to assembling a plurality of anchor assemblies. The core assembly  110  includes a shaft assembly  120 , a ratchet block assembly  122 , an outer cover block assembly  124 , a stop assembly  126  and a distal tip assembly  128 . In one embodiment, the core assembly  110  is permanently attached to the handle assembly  102 . In an alternative embodiment, the core assembly is temporarily attached to the handle assembly to allow for reuse of the handle assembly and disposal of the core assembly. 
     With specific reference to  FIG. 2B , the shaft assembly  120  further includes an elongate endoscope tube  130  which extends from a scope rear mount  132  through a front plate assembly  134  and distally to a terminal end  136  of the shaft assembly  120 . The endoscope tube accommodates a removable endoscope. Additionally, extending distally from the front plate assembly  134  and arranged generally parallel to the endoscope tube  130  is a pusher tube assembly  138  including an anchor alignment tube for maintaining alignment of anchor components within the tube. Another elongate tubular housing  140  configured to receive a needle assembly also extends longitudinally from the front plate assembly  134 . The front plate assembly further includes a sheath sealing plate  143  which is configured to create a seal between and amongst the elongate components extending therethrough (See  FIG. 2A ). 
     In an alternate approach (See  FIGS. 2C-D ), it may be possible to have the shaft assembly  120  constructed with mating extruded halves  146  to function equivalent to the current trilumen shaft assembly. 
     Further, the distal tip assembly  128  may be integral to one half of the elongate shaft. One or both of the halves  196  will have elongate channels  147  that may be semi-circular or even square shared, but would functionally constrain and house both the telescope and needle assembly in their unique channels. In a simple construction the second half may merely close off the open channels  147  to constrain the telescope and needle assembly. 
     The distal curved needle housing  148  that vectors the needle tip through the urethral wall (or other body lumen) is integral to one or both of the halves where if biased to one half the guiding surface may provide more intimacy and improved performance. 
     The pin storage tube  149  may be a Nitinol or stainless steel tube that is either or both laser cut or laser welded with assembly features. Such assembly features may be folded over tabs or points that may be captured between the shaft extrusion assembly, thus integrating the parts to functionally act like the current invention at a lower complexity or cost. 
     In a yet further approach, an alternative construction of the shaft assembly  120  may incorporate a stamped metal element that is a single elongate strip  151  of thin wall stainless steel (See  FIGS. 2E-I ). Fenetrations, castellations or tabs  153  ( FIG. 2F ) may be stamped around the edges so as to be formed  155  ( FIGS. 2G  and H) to retain hypotubes adjacent to each other at distinct points that may later be insert molded over or inserted into a simple plastic injected molded shell  159  ( FIG. 2I ). The metal formed insert would provide more structural stiffness and accuracy in assembly in contrast to singular plastic shaft assembly. Thus, the formed strip may appear as a wave pattern with intermittent tabs formed in the opposite direction of the locally formed strip resulting in a plurality of concentric paths that hypotubes may be assembled through and fixed into position. 
     In one particular aspect, the core assembly  120  is further equipped with guide rails  145  which both lend structural support to the assembly as well as guides along which various of the subassemblies are translated with the actuation of the trigger assembly. Also, the core assembly  120  includes a longitudinally translatable outer tube assembly  142  (See  FIG. 2A ), a distal end of which is received within the distal tip assembly  128  (See also  FIG. 1D ). As described in more detail below the distal tip assembly houses a plurality of rings or cylinders and a spring biased feeder. 
     With reference to  FIGS. 3A-E , the rocker arm assembly  118  of the handle assembly is described as is its interaction with the trigger system assembly  114 . The rocker arm assembly interacts with the multi-actuating trigger assembly to convert each single trigger pull into four different actions of the anchor delivery system  100 . 
     With particular reference now to  FIGS. 3D and 3E , it is to be appreciated that the rocker arm assembly  118  is grounded at two points, at a rocker arm pivot point  173  and at a crank shaft  172 . Both of these elements are free to rotate, but not translate. A mid-section of the assembly  118  is characterized by a scotch yoke structure. As is conventionally known, the scotch yoke can be employed to convert rotational motion into linear motion. Here, the rocker arm assembly  118  is powered by a spring assembly  162  and through interaction between the trigger assembly  114  and a rocker pawl  163 , this spring assembly  162  is selectively activated to effect rotation of a crank bearing assembly  176  which is attached in an off-center position to a cam bearing assembly  180 . This in turn causes the cam bearing  180  to be guided along barriers defined by an oval recess  178  formed in a lower rocker arm portion  152  of the rocker arm assembly  118 . Such action results in the rocker arm assembly  118  to pivot at its lower end about the rocker pivot point  173  and at its top end, linear motion results. This linear motion is employed to selectively translate the spool assembly  116  longitudinally. 
     In one particular aspect, the rocker arm assembly  118  includes an upper rocker arm assembly  150 , a lower rocker arm assembly  152  and upper  154  and lower  156  break away links. A terminal end  157  of the upper rocker arm  150  is provided with a slot which slideably engages complementary structure on the spool assembly  116 , the interconnection of which facilitates the transition of articulating movement of the rocker arm assembly into longitudinal motion of the spool assembly  116 . Further, a spring (not shown) connects the upper rocker arm assembly  150  to the upper break away link  154 . The damper assemblies  166  function as a mode of speed modulation which governs the action of the large gear  164  and thus the action of the rocker arm assembly  118  in response to the trigger assembly  114 . The damper assemblies  166  are filled with a selected amount of fluid having a known viscosity. The amount and viscosity of the fluid can be varied to achieve the desired dampening effect. In the approach contemplated, the lower rocker arm assembly  152  includes a pair of spaced pivot points  158 ,  160  to which the upper rocker arm  150  and the lower break away link  156  are pivotably connected. Further, a pivoting connection exists between the upper  154  and lower  156  break away links. The rocker arm assembly further includes a crank spring assembly  162  mounted on the lower rocker arm assembly  152 . 
     With the crank spring assembly  162  removed (See  FIG. 3B ), the engagement between a large gear  164  and a pair of spaced damper assemblies  166  can be better appreciated. Configured on the same side of the lower rocker arm assembly  152  and adjacent to the large gear  164  is a rocker arm ratchet  168  (See  FIG. 3C ). A crank arbor  170  is positioned on an outside surface of the rocker arm ratchet  168 . It is to be recognized that as a result of the actuation of the trigger assembly the crank spring assembly  162  drives the crank  170  counter clockwise and thereby moves the rocker arm assembly  118  forward and backwards about rocker arm pivot point  173 . 
     Each of the rocker arm ratchet  168  and crank arbor  170  (See  FIG. 3C ) are configured upon a centrally configured crank shaft  172 , the crank shaft passing through a curved slot  174  formed in the lower rocker arm  152  (See  FIG. 3D ). On the opposite side of the lower rocker arm assembly  52  and also mounted on the crank shaft  172  is an eccentrically arranged crank bearing assembly  176  (See  FIG. 3E ). See also  FIG. 3F  which depicts the juxtapositioning of the crank bearing assembly  176  and the cam bearing assembly  180 . 
     Moreover, as stated, configured on a portion of the crank bearing  176  and within an oval recess  178  formed in the lower rocker arm  152  is a cam bearing  180 . The crank bearing  176  is rotationally coupled to the crank shaft  172  and thereby converts the rotational motion to linear motion at the terminal end  157  of the upper rocker arm  150  as in a scotch yoke. Additionally, in operation the crank spring assembly  162  is kept from unloading by a spring-loaded, rocker pawl  163  (See  FIG. 3C ), the rocker pawl being tripped during certain stages of trigger activations. In this regard, the assembly is equipped with a no-skip feature. That is, as best seen in  FIG. 3C , the rocker arm ratchet  168  is equipped with a no-skip cam surface  175 . As the trigger assembly causes one end of the rocker pawl  163  to disengage from the rocker arm ratchet  168  and the rocker arm ratchet  168  rotates in response to the energy provided by the crank spring assembly, a no skip link cam follower  177  engages the no skip cam surface  175 . This action results in properly positioning the components to prevent pawl skipping and double needle deployment due to high crank speed and low reaction speed of the pawl  163  after tripping. A torsion spring  179  is provided at the vertically positioned pivot point  158  to prevent high speeds in the lower rocker arm  152  to help control the speed of rotation of the rocker arm ratchet  168 . As can be seen in the FIGS., the rocker arm ratchet  168  includes only two teeth which are alternatively engaged by the rocker arm pawl assembly  163 . These teeth are spaced such that an advance stroke occurs on one pawl trip and a retract stroke occurs on the next pawl trip. 
     Additionally, during the stage of activation of the trigger assembly when the terminal end  159  hits the stop assembly  126  and there is rotation of the lower rocker arm assembly  152 , the upper  154  and lower  156  break away links break in that the pivot joint between the two members translates inwardly toward the upper rocker arm assembly  150 . This breakaway action allows the lower rocker arm  152  to continue through an entire stroke while the upper breakaway link rocker arm  154  rotates in an opposite direction such that no further translation is imparted upon the terminal end  157 , the spool assembly  116  and the needle assembly connected thereto stop at a depth set by the stop assembly  126 . Accordingly, this mechanism controls the movement of the spool assembly as more fully described below. 
     Finally, the windows  107  formed in the handle  106  can be used to also access portions of the rocker assembly  118  or the handle housing  106  itself can be removed to do so. Thus, the crank bearing assembly  176  can be manually turned to accomplish desired movement of components turning the rocker arm assembly. A bailout feature is thus provided to, for example, retract the needle assembly. 
     Turning now to  FIGS. 4A and 4B , there is shown a spool assembly  190 . The spool assembly is used to push anchor components from the distal end of the anchor delivery device. The rotary mechanism is particularly advantageous in that it allows several anchor assemblies (e.g. four) with approximately 6 cm (corresponds to ½ of circumference of spool) of connector material such as monofilament PET, 0.015 inch diameter between anchors to be stored in a relatively small device that fits in a user&#39;s hand. The spool assembly  190  further includes a tension housing assembly  192 , a deploy housing assembly  194 , and a damper assembly  196 . 
     The tension housing assembly  192  is configured between a housing cap  198  and the deploy housing assembly  194 . The spool assembly  190  further includes a circular recess  200  in the tension housing  201  that is sized and shaped to receive a tension arbor with tension spring. In one approach, the tension spring applies one pound of tension to an implant component once the component has been deployed, but less and more tension can be provided as desired. Further, the assembly is configured so that no tension is applied prior to implantation. Also, the tension spring  204  is loaded up to ½ turn as the needle is retracted, thereby tensioning the suture, and then it unloads, thereby retracting the capsular anchor assembly after the urethral anchor is delivered and the suture is cut. The housing cap  198  retains the tension arbor  202  and tension spring  204  within the circular recess  200 . Moreover, the spool housing  190  may further include bushings  206  which fit within holes  208  formed through a pair of spaced arms  209  extending from a top of the tension housing assembly  192 . The bushings  206  provide a surface for smooth movement along rails  140  of the core assembly  110  (See  FIG. 2A ). 
     As shown in  FIG. 4B , the deploy housing assembly  194  is configured with a first circular recess  208  facing the tension housing assembly  192 . The first recess  208  is sized and shaped to receive a spool assembly with a central shaft  230 . The adjacently arranged tension housing assembly  192  retains the spool assembly  210  within the first recess  208 . It is to be recognized that a wire (not shown) is wound around the spool assembly  210 . This wire is bonded to an implant (anchor) assembly and transmits the driving force and tensioning torque from the spool assembly  190  to the implant components during the deployment of an anchor assembly. A second recess (not shown) is formed in an opposite side of the deploy housing assembly  194  which faces the damper assembly  196 . This second circular recess is sized and shaped to receive a spool ratchet disc  214  sandwiched between a deployment arbor with central shaft  216  and a suture deploy spring  218  which is initially fully loaded with enough energy to drive four distal anchor members out of the needle. The damper assembly  196  retains the spool ratchet disc  214 , deployment arbor  216  and suture deploy spring  218  within the second recess of the deploy housing assembly  194 . The deploy housing assembly  190  is further equipped with a spring loaded suture deploy pawl assembly  219  received within a recess formed in a bottom lateral surface of the housing  194 . It is to be noted that the spool ratchet disc  214  is coupled to the deployment arbor  216  in a manner such that the deployment spring (not shown) is refrained from unloading until the deploy pawl  219  is tripped. The no-skip mechanism again here prevents double deployments if the primary mechanism moves faster than the pawl&#39;s  219  response times. 
     The damper assembly  196  includes a damper body  224  and a damper rotor  220  which have multiple interleaved circular surfaces such that the damper rotor  220  can rotate within the damper body  224 . The gaps between the interleaved surfaces are filled with viscous dampening fluid (not shown). The damper rotor  220  has a square peg which positively and permanently engages into the square port of the deploy arbor  216 , thereby providing speed modulation to the deploy spring  218  as it is unloaded to deploy the distal anchor member out of the needle. 
     A central shaft  230  is configured through the tension housing assembly  192  and extends to within the deploy housing assembly  194 . A square section  231  of the shaft  230  is always engaged in the spool assembly  190  with either the deployment arbor  216  or the tension arbor  202 . Thus, when the deployment pawl  219  is released, the square section of the central shaft  230  is engaged with the deployment arbor  216  and is disengaged from the tension arbor  202 . This allows the deployment spring to drive the spool  210  180 degrees. A throwout arm assembly  232  is retained on the central shaft  230  and includes a forked substructure  234  configured to engage complementing structure of the trigger assembly  114 . The throwout arm assembly is activated by the trigger assembly to translate the shaft  230  between the deployment arbor  216  and the tension arbor  202  at desired time points in the delivery process. 
     The window  107  formed in the handle case assembly  106  (See  FIG. 1A ) can be configured to provide convenient direct access to components of the spool assembly  190  in the event any of the components become stuck. For example, force can be directly applied to the throwout arm  232  so that the shuttle action of the assembly can be facilitated. 
     With reference now to  FIGS. 5A-E , the components of the trigger system assembly  114  are described. The trigger assembly  114  includes a trigger rack assembly  240 , a trigger cam assembly  242 , a lower cam assembly  244  and a bell crank assembly  246 , each of which are attached or separately associated with a mounting block assembly  248 . A pawl assembly  249  is further provided to alternatively engage the lower cam assembly. A pin drive rear link  250  is also provided and which is pivotably attached to the lower cam assembly  244 . For ease of understanding of the relative positioning of the various components, the mounting block assembly  248  has been removed from the structure depicted in  FIGS. 5B and 5C  and the bell crank assembly  246  has been removed from  FIG. 5C . 
     The trigger rack assembly  240  includes a mechanical rack  252  extending from a trigger  254  sized and shaped to receive a portion of an operator&#39;s hand. Also extending from the trigger  254  is a phasing dowel  256  which is configured to limit the depression of the trigger  254 . The trigger rack assembly  240  further includes a spring  258  for biasing the assembly away from the mounting block assembly  248 . 
     The rack  252  of the trigger rack assembly  240  engages the trigger cam assembly  242 . The trigger cam assembly  242  further includes a trigger pinion  259  (See  FIG. 5D ) with teeth which mate with the teeth of the rack  252 . The trigger pinion  259  is placed adjacent to a cam subassembly  260 , each of which are positioned on a central trigger shaft  262 . 
     The lower cam assembly  244  includes a link  264 , one end of which travels through an open V-shaped slot formed in the lower cam plate  266 . Also formed in the lower cam plate  266  is a through hole  267  for receiving a shaft of a reset assembly (described below in connection with  FIGS. 6A and 6B ). The opposite end of the link  264  is configured to slide within a slot  269  formed within the pin drive rear link  250 . A top end  268  of the pin drive rear link  250  is operatively associated with structure for advancing components of the anchor assembly through the core assembly  120 . 
     The bell crank assembly  246  includes a T-shaped frame  270  at the top of which are a pair of spaced arms  272  ( FIG. 5A ). Configured between the arms is a bell crank rail  274 . On a back side of the structure is configured a bell crank follower  275  (See  FIG. 5G ). 
     As best seen in  FIG. 5D  where the mounting block cover  276  is removed, the trigger assembly  114  further includes a deploy plate assembly  280 . This assembly includes a deployment plate  282  to which are pivotably attached a first link  284  and a second link  286 . A double pawl assembly  288  is further provided, the operation of which is controlled by a sprag actuator  290  which is mounted to the trigger rack  242 . 
     The double pawl assembly  288  is configured to act as a trigger control mechanism. In a first default position, the double pawl assembly  288  engages the rack assembly  240  in a manner which permits the trigger  254  to be depressed while allowing for and holding partial depression and preventing incomplete depression (See  FIG. 5E ). Once the trigger  254  is completely depressed, the sprag actuator  290  engages the double pawl assembly causing it to rotate such that the default engagement between the rack assembly  240  and the double pawl assembly  288  is eliminated (See  FIG. 5F ). Thereafter, the rack assembly  240  can return via the bias spring  258  to its original position (See  FIG. 5D ). As the default engagement of the rack assembly  240  and double pawl assembly  288  is eliminated, a second alternative engagement is created. In the second engagement, the double pawl assembly permits the trigger  254  and rack assembly  240  to return to the original position and prevents an incomplete return to the original position. That is, the double pawl assembly controls the trigger stroke bi-directionally. Thus, the engagement between the double pawl assembly  288  and the sprag actuator  290  then limits the degree to which the trigger can be depressed as well as facilitates the return of the trigger  254  to its default or un-depressed position. 
     Accordingly, the single trigger  254  actuates all steps of deployment through operative association with the rocker pawl assembly  163  and the throwout arm assembly  232 . That is, activation of the trigger  254  causes the bell crank assembly  270  to pivot laterally taking with it the throwout arm assembly  232 . By way of its connection to the central shaft  230 , the throwout arm accomplishes the shuttling of the shaft  230  between functions performed by the spool assembly  190 . Moreover, actuation of the trigger  254  further accomplishes the alternative engagement and disengagement between the rocker pawl  163  and the crank arbor  170 . This engagement and disengagement permits the longitudinal movement of the spool assembly  190  between rear and forward positions. As a needle assembly and pusher assemblies are operatively linked to this mount, this longitudinal movement is likewise controlled by the trigger  254  actuation. 
     Further trigger control is provided by the interaction between the phasing dowel  256  and the trigger cam subassembly  260 . That is, the trigger cam  260  includes a plurality of slots  291  formed in a periphery thereof. These slots  291  receive a terminal end of the phasing dowel  256  so that continued rotation of the trigger cam  260  in response to trigger depression is inhibited by the engagement between these parts. A roller clutch (not shown) configured within the trigger cam  260  provides yet further control by inhibiting the cam  260  from moving except during an inward trigger stroke. 
     The window  107  in the handle case  106  ( FIG. 1A ) can further be configured to provide access to components of the trigger assembly  114 . That is, the double pawl assembly  388  can be manually engaged, for example, to thereby override a jam. Likewise, other components of the assembly  114  can be so engaged to facilitate proper function. 
     The handle assembly  102  further includes a reset assembly  300  (See FIGS.  1 C and  6 A-B) for resetting the delivery system after deploying and implanting an anchor assembly to be ready to deploy another anchor assembly. The reset assembly  300  includes a reset knob  302  rotatably mounted to a reset plate  303  and having an interior configured to receive an engagement spring  304 . A lever  305  is further provided for easy manipulation of the assembly. Also, a pair of bearings  306 ,  308  are provided to mate with the reset knob  302  and to provide a surface for engaging a shaft  309  extending laterally through hole  267  of the trigger assembly  114 . A knob latch  310  is configured to releasably engage the knob  302 . 
     The reset assembly  300  also includes a one way reset wheel assembly  312  mounted to the reset plate  303  to which a reset link  314  is rotatably connected. The reset wheel assembly  312  prevents backwards motion of the shaft until the reset action is complete. The reset action recharges the spring  304  which powers the urethral cam  244  ( FIG. 5D ). Near an opposite terminal end of the reset link  314  is a threaded projector  316  adapted to engage complementary structure of the knob  302  (See  FIG. 6B ). The reset assembly  300  also includes a one way reset clutch  320  configured concentrically within a reset bearing  322 . Also contained within the reset assembly is a U-shaped reset wire form  324 . Bumpers  326  are provided to deflect the U-shaped wire form  324  which acts on the bumpers  326  to push the one way reset wheel  312  out of the top dead center and bottom dead center positions where the link  314  cannot rotate the wheel  312 . 
     In the above description springs have been described as the mechanism for actuating the various assemblies when the trigger is pulled, however, it is also within the scope of the invention to use other mechanisms such as motor, compressed gas, elastomers and the like. 
     One preferred embodiment of an anchor assembly of the present invention is depicted in  FIGS. 7A-D . In its unconstrained configuration, the first or distal anchor component  370  includes a first tubular portion  372  which is generally orthogonal to a second tail portion  374 . It is to be noted, however, that while housed in a delivery assembly and prior to deployment at a target area, the first anchor component  370  is constrained to define a generally straight configuration, only subsequently assuming the unconstrained configuration upon deployment from the delivery device. 
     The tubular portion  372  of the first anchor component  370  includes a plurality of tabs  376  which can be deformed or deflected to accomplish affixing the component  370  to a connector assembly  378  (See  FIG. 7B ). It has been found that three such tabs  376 , two on one side of the tubular portion  372  and one on an opposite side provide a sufficient connecting force and a desired balance between the connector  378  and first anchor component  370  and to move the first anchor component  370  by applying a force either in the proximal or distal direction. 
     It is contemplated that the first anchor component  370  can be laser cut from a tube formed of nitinol or other appropriate material. A mid-section  380  of the component  370  provides a structural transition from the tubular portion  372  to the tail portion  374 . As such, a portion of a side wall is removed in the mid-section area  380 . A further portion of the side wall is removed to define a connecting section  382  of the tail  374  which extends from the mid-section  380 . This connector section  382  acts as a spring to accomplish the relative unconstrained angle assumed between the tail  374  and tubular portion  372 . A terminal end portion  383  of the tail  374  embodies structure having a surface area which is larger than that of the connector section  382  to thereby provide a substantial platform for engaging tissue at a target site. 
     As shown in  FIGS. 7C  and D, the second anchor component  384  includes a first part  386  and a second part  388 . Once the first anchor component  370  is positioned at a target site by employing a delivery device such as that disclosed below (or previously), the second anchor component  384  is assembled in situ. 
     The first part  386  of the second anchor component  384  includes an internal bore  390  sized to receive a portion of the second part  388  of the second anchor component  384  in a locking engagement. An external surface of the first part  386  is sized and shaped to include a proximal collar  391  spaced from a mid-section  392 , each of which have generally cylindrical profiles. A smaller diameter, outer cylindrical portion  393  is configured between the proximal collar  391  and mid-section  392  of the component and a distal cylindrical portion  394  having yet a smaller cylindrical profile defines a distal end thereof. 
     The second part  388  of the second anchor component  384  includes a solid generally cylindrical back end  395 , extending from which are a pair of spaced prongs  396 . Terminal ends of the prongs  396  can be tapered to both facilitate the insertion of the prongs  396  within the internal bore  390  of the first part  386  as well as to receive a section of the connector assembly  378 . Notably, the prong structure commences at a narrowed slot  397  which steps outwardly to a wider dimension to thereby define the space between the prongs  396 . This narrow slot  397  provides the second part  388  with desired structural rigidity to receive the connector assembly  378  and to facilitate lockingly engaging the connection between the first  386  and second  388  parts. The space between the prongs  396 , in one embodiment can be dimensional relative to the diameter of the connector  378  such that is has sufficient clamping force such that the first part  386  is not needed and therefore is optional for providing additional security. 
     Thus, in its pre-implanted form, the anchor assembly can include one anchor member (e.g., first anchor) whose initial engagement with a connector is generally coaxial and another anchor member (e.g., second anchor) with an initial engagement being generally perpendicular with the connector. 
     These assemblies can further be employed to deliver therapeutic or diagnostic substances to the interventional site. For example, in a procedure to treat a prostate gland, substances that cause the prostate to decrease in size such as 5-alpha-reductase inhibitors can be introduced at the treatment site. A particular advantageous procedure is to use the needle of the anchor delivery device to inject 100 to 200 units of botulinum toxin (such as available from Allergan, Inc.) dissolved in 4 mL of saline either before, during or after deploying the anchor assembly. Preferably, 2 mL are injected in each lobe of the prostate. Another advantageous procedure is to use the needle of the anchor delivery device to inject 100 to 300 units of botulinum toxin dissolved in 10 to 30 mL of saline into the base of the bladder, bladder lateral walls and/or trigone. Preferably, 0.5 to 1.0 mL are injected into about 20 to 30 sites in the bladder for treating over-active bladder. Other substances but not limited thereto, which may be introduced at the site include various scarring agents, rapamycin and its analogues and derivatives, paclitaxel and its analogues and derivatives, phytochemicals, alpha-1a-adrenergic receptor blocking agents, smooth muscle relaxants and other agents that inhibit the conversion of testosterone to dihydrotestosterone. 
     In a first step to deliver and deploy an anchor assembly for the purpose of manipulating tissue or other anatomical structures, the endoscope device is employed to view the positioning of a multi-actuating trigger anchor delivery device  100  at the interventional site, for example, the elongate tissue access assembly  104  of the device is inserted into the penis of a patient and advanced until the distal end  128  is adjacent an interventional site in the urethra (UT) adjacent the bladder (UB; See  FIG. 8 ). It has been found that a mechanical solution to the treatment of BPH such as that of the present invention, can be more compatible with patients recovering from prostate cancer compared to energy-based solutions. Furthermore, the present invention also contemplates steps for sizing the anatomy. As it relates to BPH treatment, the present invention also involves the placement of an ultrasonic or other device in the patient&#39;s body, such as in the rectum, to measure the necessary depth of insertion of the distal end of the needle assembly within the patient&#39;s body. This information can be used to set or create a depth stop for the needle assembly by the operator using a knob (not shown) on the outside of the handle connected to the stop assembly  126  so that during deployment the distal end of the needle assembly extends all the way through the prostate from inside the urethra to outside of the prostate capsule. 
     After so positioning the deployment device within the patient, the multi-actuating trigger anchor delivery device  100  is employed to assemble and implant an anchor assembly at an interventional site. In a first step, the trigger  254  of the trigger assembly  114  is depressed until through its inter-connection with the rocker arm assembly  118  via the trigger cam subassembly  260 , the rocker pawl follower  163  is released from a locking engagement with the rocker arm ratchet  168  (See  FIG. 9A ). Releasing the rocker arm ratchet  168  results in the unloading of the crank spring assembly  162  thereby causing rotation of the eccentric crank  176  and thereby the rocker arm assembly  118  and the forward translation of the upper portion of the rocker arm assembly  118  and the spool assembly  116  (See  FIG. 9B ). This is permitted through the interaction of the upper rocker arm assembly  150 , the lower rocker arm assembly  152 , and upper  154  and lower  156  break away links and a depth stop assembly  410  (See also  FIGS. 2A and 3A ). That is, the depth stop assembly  410  engages the upper break away link  154  so that it breaks (or rotates) with respect to the lower link  156  to limit the forward motion of the spool assembly. Such action accomplishes the advancement of a needle assembly  400  within the elongate tubular housing  140  via its connection with the spool assembly  116  (See  FIG. 9D ). Moreover, the depth stop assembly  410  can be positioned as desired to control the depth to which the needle assembly  400  is projected. The selected position may be based on anatomical measurements made by various imaging techniques such as ultrasound. 
     Release of the trigger  254  permits the trigger  114  to return to a ready position, leaving the spool assembly  116  in its forward position (See  FIG. 9C ). The articulation of the double pawl assembly  288  from its default position (See also  FIG. 5D ) facilitates this return of the trigger assembly  114  to the ready position. Within the patient&#39;s anatomy, the advancement of the needle assembly  400  consequently results in the needle passing through the prostate gland (PG) (See  FIG. 9E ). In one contemplated approach, a terminal end of the needle  400  is positioned to extend beyond the prostate gland (PG) but it is to be recognized that the degree of needle insertion can be modified for a particular purpose. 
     Next, the trigger assembly  114  is employed again to effect the deployment of the distal anchor component  370  (See  FIGS. 10A-F ). With the spool assembly housing  116  in a forward position, a first half of a trigger  254  pull ( FIG. 10A ) causes the spool shaft  230  to move to the deploy side  194  of the spool assembly  190  (FIGS.  10 A and  4 A-B). This is accomplished via cooperation with the bell crank assembly  246  (See also  FIG. 5A ) which drives the throw out arm assembly  232  (See also  FIGS. 4A-B ). More specifically, with the depression of the trigger  254 , the trigger cam  260  rotates. The bell crank follower  275  (See  FIG. 5G ) connected to the bell crank frame  270  rides along a variable surface formed on a side of the rotating trigger cam  260 , the variability of the surface causing the bell crank frame  270  to pivot away from the spool assembly housing  116  at a desired juncture. This causes the bell crank frame  270  to pivot the throw out arm assembly  232  which in turn advances the spool shaft  230  to the deploy side of the spool assembly  190 . 
     As the trigger  254  is continued to be depressed ( FIG. 10B ), the deploy plate  280  of the trigger assembly  114  (See also  FIG. 5D ) is positioned in a raised configuration. This raised position results from the vertical movement of a deploy plate push rod (not shown) which at one end rides along a periphery of the trigger cam  260  and at another end engages the deploy plate  280 . As the push rod engages upon raised sections of the periphery of the trigger cam  260 , the rod is translated vertically which causes the deploy plate  280  to rise. Being so positioned, the deploy plate assembly  280  actuates the suture deploy pawl assembly  219  (See also  FIGS. 4A-B ), which in turn, permits the release of the deploy spring  218  and coupled rotation, via the spool shaft  230 , of the deploy spring  218  and the spool assembly  210  thereby advancing the suture from the delivery system  100 . The two-toothed spool deploy ratchet  214  permits one half-turn of the spool assembly  210  before reengaging with the suture deploy pawl assembly  219  and arresting the suture advancement. At the finish of this second trigger  254  pull the deploy plate assembly  280  and the deploy pawl assembly  219  are back in their default positions ( FIG. 10C ). 
     At the distal end  128  of the multi-actuating trigger anchor delivery system  100 , such action facilitates the advancement of the first or distal anchor component  370  attached to the connector  378  out of the needle assembly  400  (See  FIG. 10D ). As shown in  FIG. 10E , a wire assembly  402  engages the connector  378  through a permanent connection such as a polyimide tube with adhesive. By way of its interconnection with the spool assembly  210  of the tension housing assembly  192  (See also  FIGS. 4A-B ), the desired length of the connector  378  is paid out. It is to be recognized that the wire assembly  402  has been shown in  FIG. 10E  for demonstrative purposes as its actual position may be further within the needle assembly  400  at this stage of device use. A connector diameter of approximately 40% of the inside diameter of the needle assembly  400  or greater is beneficial to pay out the connector  378  to prevent kinking of the connector material. The connector is preferably about 0.015 inch diameter PET monofilament. Moreover, at this stage no tension is supplied to the connector  378  and first anchor component  370  by the tension housing assembly  192 . 
     Accordingly, as shown in  FIG. 10F , the first anchor component  370  is ejected from the needle housing beyond an outer surface of a prostate gland (PG). Of course, when desirable, the first anchor component  370  can surgically be placed within the prostate gland (PG) or in other procedures at any position within a patient. 
     Referring now to  FIGS. 11A-E , the multi-actuating trigger anchor delivery system  100  is manipulated to withdraw the needle assembly  400  from the interventional site. As shown in  FIG. 11A  after the first anchor component is ejected from the needle assembly  400 , the trigger  254  is again returned to a ready position. With the commencement of the third trigger  254  pull ( FIG. 11B ), the central shaft  230  is shuttled back to the tension side  192  of the spool assembly  116  (See also  FIGS. 4A-B ). Again, it is the cooperation of the bell crank assembly  246  and the throw out arm assembly  232  that facilitates the shuttling of the central shaft  230 . Further depression of the trigger  254  results in the spool assembly  116  and rocker arm assembly  118  returning to a default position, again by lifting the rocker pawl  163  and releasing the crank spring assembly  162 . Consequently, the needle assembly (not shown) which is attached to the spool assembly  116 , is withdrawn completely within the needle tubular housing  140  (See  FIG. 11D ). Thus, the first anchor component  370  is left at the intervention site with the connector assembly  378  extending proximally within the elongate tissue access assembly  104  ( FIG. 11E ). During this juncture, a desired tension is placed upon the connector  378  and first anchor component  370  by tension housing assembly  192  of the spool assembly housing  116 . Moreover, the tension assembly  192  permits additional suture to be paid out relative to the retracting spool assembly  116 . It is this combination of suture pay-out and the function of the tension spring which facilitates the delivery of a custom-length, fixed-load implant. 
     Again with the trigger  254  automatically returning to a ready position (See  FIG. 12A ), the next step of the implant procedure can be accomplished. That is, as the trigger  254  is depressed for the fourth time ( FIG. 12B ), the pawl assembly  249  of the trigger assembly  114  is released from a locking engagement with the lower cam assembly  244  of the trigger assembly  114  (See also  FIG. 5A ). The complete depression of the trigger  254  ( FIG. 12C ) then effects the horizontal driving of the shaft  264  by the lower cam plate  266  of the lower cam assembly  244  (See also  FIG. 5C ). Consequently, the pin drive rear link  250  is translated forwardly and through its connection to the ratchet block assembly  122  (see also  FIG. 2A ), a pusher assembly (not shown) placed in apposition with rear-most second part  388  of the second anchor component is also advanced forwardly. 
     Irrespective of the specific form of the anchor assembly, a next step in the context of prostate treatment involves positioning the proximal anchor assembly, for example, within a desired section of the urethra of the patient. Prior to doing so, the patient can be monitored to determine whether there has been any evidence of improvement through the placement of the anchor. One such symptom is whether there has been any urination. After so checking, the proximal anchor assembly can be implanted. 
     Therefore, as shown in  FIGS. 12D and 12E , by way of the pusher assembly, a second part  388  of the second anchor component is advanced into engagement with the connector  378  of the anchor assembly. The second part  388  is then further advanced into engagement with the first part  386  of the second anchor ( FIG. 12G ). At this juncture, the outer tube assembly (not shown) is pulled proximally to cut the connector  378  (See  FIG. 12G ) and release the assembled second anchor assembly from the distal end  128  of the multi-actuator trigger anchor delivery system  100 . The proximal motion of the outer tube assembly is accomplished through the cooperation of an outer tube link  420  and the lower cam assembly  244 . That is, as the lower cam assembly  244  rotates forwardly, its camming surface engages and rotates the outer tube link  420  in an opposite direction. By way of its connection to the outer tube assembly, the outer tube link  420  drives the outer tube assembly rearwardly. 
     As shown in  FIG. 12H , the assembled anchor assembly is placed across the prostate gland (PG) with the first anchor component  370  configured against an outer surface of the prostate gland (PG) and the second anchor component  384  implanted with the urethra (UT). Again, it is to be recognized that the anchor assembly can be placed in other orientations throughout a patient&#39;s anatomy. 
     Finally, the lever  305  of the reset assembly  300  is actuated to reset the system for assembling and implanting another second anchor component  384 . That is, the lever  300  is pulled back to recharge the spring  304  of the reset assembly  300  to thereby return all of the assemblies to the correct position for accomplishing the assembly and release of the second anchor component  384 . Moreover, it is to be recognized that the steps and mechanisms involved in delivering other components of the anchor assembly are effected with pre-loaded energy so that a desired number (e.g. four) of such components can be implanted. 
     Accordingly, the present invention contemplates both pushing directly on anchor portions of an anchor assembly as well as pushing directly upon the connector of the anchor assembly. Moreover, as presented above, the distal or first anchor component is advanced and deployed through a needle assembly and at least one component of the proximal or second anchor component is advanced and deployed through a generally tubular portion of the anchor deployment device. Further, both a single anchor assembly or multiple anchor assemblies can be delivered and deployed at an intervention site by the deployment device. Consequently, in the context of prostate treatment, the present invention accomplishes both the compression of the prostate gland and the opening of the prostatic urethra, the delivering of an implant at the interventional site, and applying tension between ends of the implant. Moreover, drug delivery is both contemplated and described as a further remedy in BPH and over active bladder treatment. 
     Once implanted, the anchor assembly (See  FIGS. 14A and 14B ) of the present invention accomplishes desired tissue manipulation, compression or retraction as well as cooperates with the target anatomy to provide an atraumatic support structure. In particular, the shape and contour of the anchor assembly  500  can be configured so that the assembly invaginates within target tissue, such as within natural folds formed in the urethra by the opening of the urethra lumen by the anchor assembly. In fact, in situations where the anchor assembly is properly placed, wispy or pillowy tissue in the area collapses around the anchor structure. Eventually, the natural tissue can grow over the anchor assembly  500  and new cell growth occurs over time. Such cooperation with target tissue facilitates healing and avoids unwanted side effects such as calcification or infection at the interventional site. 
     Furthermore, in addition to an intention to cooperate with natural tissue anatomy, the present invention also contemplates approaches to accelerate healing or induce scarring. Manners in which healing can be promoted can include employing abrasive materials, textured connectors, biologics and drugs. 
     It has been observed that placing the anchors at various desired positions within anatomy can extract the best results. For example, when treating a prostate, one portion of an anchor can be placed within an urethra. It has been found that configuring such anchors so that ten o&#39;clock and two o&#39;clock positions (when looking along the axis of the urethra) are supported or retained, effectively holds the anatomy open and also can facilitate invagination of the anchor portion within natural tissue. This is particularly true in the regions of anatomy near the bladder and the juncture at which the ejaculatory duct connects to the urethra. 
     Additionally, it is contemplated that all components of the anchor assembly or selected portions thereof (of any of the anchor assemblies described or contemplated), may be coated or embedded with therapeutic or diagnostic substances (e.g. drugs or therapeutic agents). Again, in the context of treating a prostate gland, the anchor assembly can be coated or imbedded with substances such as 5-alpha-reductase which cause the prostate to decrease in size. Other substances contemplated include but are not limited to phytochemicals generally, alpha-1a-adrenergic receptor blocking agents, smooth muscle relaxants, and agents that inhibit the conversion of testosterone to dihydrotestosterone. In one particular approach, the connector  95  can for example, be coated with a polymer matrix or gel coating which retains the therapeutic or diagnostic substance and facilitates accomplishing the timed release thereof. Additionally, it is contemplated that bacteriostatic coatings can be applied to various portions of the anchor assemblies described herein. Such coatings can have various thicknesses or a specific thickness such that it along with the connector itself matches the profile of a cylindrical portion of an anchor member affixed to the connector. Moreover, the co-delivery of a therapeutic or diagnostic gel or other substances through the implant deployment device or another medical device (i.e. catheter), and moreover an anchor assembly including the same, is contemplated. In one such approach, the deployment device includes a reservoir holding the gel substance and through which an anchor device can be advance to pick up a desired quantity of therapeutic or diagnostic gel substance. 
     It is to be recognized that the timing of the dual advancement of the needle and connector assemblies and subsequent relative motion between the assemblies is coordinated. That is, the needle assembly first provides access to an interventional site and then the connector assembly is extended beyond a terminal end of the needle assembly through the relative motion of the needle and connector assemblies. 
     It is further contemplated that in certain embodiments, the anchor delivery device can include the ability to detect forces being applied thereby or other environmental conditions. Various sections of the device can include such devices and in one contemplated approach sensors can be placed along the needle assembly. In this way, an operator can detect for example, whether the needle has breached the target anatomical structure at the interventional site and the extent to which such breaching has occurred. Other sensors which can detect particular environmental features can also be employed such as blood or other chemical or constituent sensors. Moreover, one or more pressure sensors or sensors providing feedback on the state of deployment of the anchor assembly during delivery or after implantation are contemplated. For example, tension or depth feedback can be monitored by these sensors. Further, such sensors can be incorporated into the anchor assembly itself, other structure of the deployment device or in the anatomy. 
     Moreover, it is to be recognized that the foregoing procedure is reversible. In one approach, the connection of an anchor assembly can be severed and a proximal (or second) anchor component removed from the patient&#39;s body. For example, the physician can simply cut the connector and simultaneously remove the second anchor previously implanted for example, in the patient&#39;s urethra. 
     An aspect that the various embodiments of the present invention provide is the ability to deliver multiple, preferably four, anchor assemblies having a customizable length and distal anchor components, each anchor assembly being implanted at a different location without having to remove the device from the patient. The various embodiments provide for variable needle depth and variable connector length for each of the multiple anchor assemblies delivered. Other aspects of the various embodiments of the present invention are load-based delivery, preferably 1 pound, of an anchor assembly, anchor assembly delivery with a device having integrated connector, (e.g. suture), cutting, and anchor assembly delivery with an endoscope in the device. The delivery device is uniquely configured to place such a load (half pound to five pounds) between spaced first anchor members as well as between or on an implanted first anchor and the delivery device. In this aspect, the needle assembly acting as a penetrating member can be cooperatively connected to a mechanism which produces a desired tension between the various anchor members while the needle assembly is retracted. Moreover, this load can be accomplished between first and second implanted anchor members. 
     It is to be recognized that various materials are contemplated for manufacturing the disclosed devices. Moreover, one or more components such as distal anchor, proximal anchor, connector, of the one or more anchor devices disclosed herein may be designed to be completely or partially biodegradable or biofragmentable. 
     Further, as stated, the devices and methods disclosed herein may be used to treat a variety of pathologies in a variety of tubular organs or organs comprising a cavity or a wall. Examples of such organs include, but are not limited to urethra, bowel, stomach, esophagus, trachea, bronchii, bronchial passageways, veins (e.g. for treating varicose veins or valvular insufficiency), arteries, lymphatic vessels, ureters, bladder, cardiac atria or ventricles, uterus, fallopian tubes, etc. 
     Finally, it is to be appreciated that the invention has been described hereabove with reference to certain examples or embodiments of the invention but that various additions, deletions, alterations and modifications may be made to those examples and embodiments without departing from the intended spirit and scope of the invention. For example, any element or attribute of one embodiment or example may be incorporated into or used with another embodiment or example, unless to do so would render the embodiment or example unpatentable or unsuitable for its intended use. Also, for example, where the steps of a method are described or listed in a particular order, the order of such steps may be changed unless to do so would render the method unpatentable or unsuitable for its intended use. All reasonable additions, deletions, modifications and alterations are to be considered equivalents of the described examples and embodiments and are to be included within the scope of the following claims. 
     Thus, it will be apparent from the foregoing that, while particular forms of the invention have been illustrated and described, various modifications can be made without parting from the spirit and scope of the invention.